Actively Recruiting
A Physiologic Comparison of Two Approaches to Treating Peripheral Neuropathy
Led by Loma Linda University · Updated on 2025-11-19
40
Participants Needed
1
Research Sites
185 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Diabetic peripheral neuropathy is one of the most common and costly microvascular complications of diabetes impacting more than 50% of patients and costing more than 10.1 billion dollars annually. Intraneural Facilitation Therapy (INF® Therapy) is a non-invasive technique that has shown to improve balance and pain in patients with Type 2 Diabetic Peripheral Neuropathy (T2DPN); however, the underlying physiological mechanisms need further understanding. The purpose of this study is to investigate the physiological mechanisms behind two approaches to treating T2DPN, INF® Therapy and standard physical therapy. Eligible subjects presenting with diabetic neuropathy symptoms will be recruited and referred to the Loma Linda University Health's Neuropathic Therapy Center. Forty patients will be evenly randomized into two groups: an INF® Therapy Treatment group and standard physical therapy treatment group. Subjects will participate in 11 study visits over a period of 6 weeks. Non-invasive assessments will measure neuropathy pain, heart rate variability, neuropathy severity, blood oxygen levels, and blood flow under the skin. Lab draws will measure inflammation levels in the blood and how well blood sugar levels have been maintained over a period of about 3 months. Descriptive statistics and repeated measures ANOVA will be used to analyze data and answer the research questions. The findings of this study will provide a better understanding of how INF® Therapy and standard physical therapy work, subsequently improving non-invasive treatment methods for T2DPN patients.
CONDITIONS
Official Title
A Physiologic Comparison of Two Approaches to Treating Peripheral Neuropathy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Between the ages of 45 and 85
- Moderate to severe type II diabetic neuropathy with symptoms such as numbness, tingling, burning, sharp pain, or increased sensitivity
- Diagnosis of diabetic neuropathy confirmed by a physician
- Access to a cellphone with Android 5.0 or newer or iOS 14.0 or later
You will not qualify if you...
- Medical conditions likely to cause decline within 6 months, including chemotherapy or radiation
- Lower extremity amputations
- Open wounds
- Documented active drug or alcohol misuse
- Chronic liver disease
- Active inflammations
- Neuropathies not related to diabetes, including B12 deficiency and Charcot Marie Tooth
- Morbid obesity
- Pregnancy
- Use of beta blockers
- Inability to maintain steady fingers or operate a cellphone
- Smoking or marijuana use
- Presence of a pacemaker
- Allergies to cobalt, chrome, or nickel
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Loma Linda University Health Neuropathic Therapy Center
Loma Linda, California, United States, 92350
Actively Recruiting
Research Team
M
Mark Bussell, DPT, OCS
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here